What were the key takeaways from Zevra's earnings call?

What is Zevra's gross profit margin?

What is Zevra's latest dividend and current dividend yield?

What is the market's earnings forecast for Zevra next quarter?

What does Zevra do and what are its main business segments?

What guidance did Zevra's management provide for the next earnings period?

What is the revenue and EPS growth rate for Zevra year over year?

Did Zevra beat or miss consensus estimates last quarter?

- **Miplyf Dominance**: $26.1M Q3 revenue, 137 prescriptions, 66% coverage; European MAA submission progressing.
- **Financial Resilience**: $230M cash, disciplined spending; gross-to-net adjustment resolved.
- **Pipeline Focus**: Celiprolol enrollment 44/150; KP1077 phase II completed; VEDS interim data positive.

**【Management Opening Remarks】**
- Zevra's Vice President of IR, Nicole Ochsner, welcomed participants and highlighted the risks associated with forward-looking statements, emphasizing reliance on SEC filings for material uncertainties.

**【CEO Commentary】**
- **Miplyf Success**: Q3 net revenue of $26.1M, with $22.4M from Miplyf, driven by 8 new prescriptions (total 137) and 66% covered lives. European MAA submission under review, with 92 EAP patients in Europe.
- **Pipeline Focus**: Celiprolol phase III enrollment at 44/150; KP1077 phase II completed; VEDS interim analysis with 1 event.
- **Strategic Shifts**: Scaling back Apruva sales efforts; prioritizing Miplyf and high-impact R&D.

**【CFO Financial Commentary】**
- **Financial Health**: $230.4M cash, $61.3M debt; Q3 net loss $0.5M vs. $33.2M prior year. Gross-to-net adjustment ($1.2M) due to Medicare Part D changes.
- **Cost Management**: Operating expenses down 6.8%; R&D (-7.5%), SG&A up 4.6% for commercial expansion.

**【Q&A Highlights】**
- **Patient Access**: 40% diagnosed patients on therapy; 66% coverage via formulary/exception pathways.
- **Europe Strategy**: Evaluating independent launch vs. collaboration; potential 2026 approval and commercialization.
- **Pipeline Updates**: KP1077 strategic options under review; VEDS interim data positive but event-driven trial ongoing.

Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

ZVRA

ZVRA fundamentals

You can ask Aime